Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

被引：0
|
作者：
Haakensen, V. [1 ]
Nowak, A. [2 ]
Ellingsen, E. [3 ]
Grundberg, O. [4 ]
Farooqi, S. [1 ]
Mcculloch, T. [5 ]
Cedres, S. [6 ]
Bjaanaes, M. [1 ]
Helland, A. [7 ,8 ]
机构：
[1] Oslo Univ Hosp, Div Canc Med, Oslo, Norway
[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Crawley, ACT, Australia
[3] Ultimovacs Asa, Oslo, Norway
[4] Karolinska Inst, Stockholm, Sweden
[5] Aalborg Univ Hosp, Aalborg, Denmark
[6] Vall Dhebron Inst Oncol Vhio, Med Oncol, Vall Dhebron Barcelona Hosp Campus, Barcelona, Spain
[7] Univ Oslo, Clin Med, Oslo, Norway
[8] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Immunotherapy; Mesothelioma; clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P24.07
引用
收藏
页码：S380 / S380
页数：1
相关论文
共 50 条
  • [41] Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
    Zalcman, G.
    Mazieres, J.
    Greillier, L.
    Lantuejoul, S.
    Do, P.
    Bylicki, O.
    Monnet, I.
    Corre, R.
    Audigier-Valette, C.
    Locatelli-Sanchez, M.
    Molinier, O.
    Thiberville, L.
    Urban, T.
    Planchard, D.
    Ligeza-Poisson, C.
    Amour, E.
    Morin, F.
    Moro-Sibilot, D.
    Scherpereel, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] PHASE II STUDY OF CARBOPLATIN AND VINORELBINE 1ST LINE TREATMENT IN ADVANCED MALIGNANT PLEURAL MESOTHELIOMA
    Sorensen, Jens B.
    Bech, Cecilia
    Sorensen, Peter
    Frank, Hanna
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1354 - S1355
  • [43] Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta
    Vrdoljak, Eduard
    Magri, Claude
    Gamulin, Marija
    Boskovic, Lidija
    Omrcen, Tomislav
    Bajic, Zarko
    Dienes, Tamas
    Geczi, Lajos
    NEOPLASMA, 2021, 68 (01) : 208 - 215
  • [44] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
    Scherpereel, A.
    Antonia, S.
    Bautista, Y.
    Grossi, F.
    Kowalski, D.
    Zalcman, G.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mansfield, A.
    Popat, S.
    Sun, X.
    Padilla, B.
    Aanur, P.
    Daumont, M.
    Bennett, B.
    McKenna, M.
    Baas, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1441 - S1441
  • [45] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
    Bischoff, H.
    Scherpereel, A.
    Antonia, S.
    Bautista, Y.
    Grossi, F.
    Kowalski, D.
    Zalcman, G.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mans-Field, A.
    Popat, S.
    Sun, X.
    Padilla, B.
    Aanur, P.
    Daumont, M.
    Bennett, B.
    McKenna, M.
    Baas, P.
    PNEUMOLOGIE, 2021, 75 : S17 - S17
  • [46] 2ND LINE HORMONE-TREATMENT IN RECEPTOR POSITIVE BREAST-CANCER PATIENTS
    VONROENN, J
    BONOMI, P
    WOLTER, J
    ANDERSON, K
    BREAST CANCER RESEARCH AND TREATMENT, 1985, 6 (02) : 168 - 168
  • [47] Do Factors That Significantly Predict 1st Line Treatment Also Predict 2nd Line Treatment for Elderly Metastatic Colon Cancer Patients?
    Zheng, Z.
    Onukwugha, E.
    Hanna, N.
    Reese, E.
    Seal, B.
    Mullins, D.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S121 - S122
  • [48] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
    Peters, S.
    Scherpereel, A.
    Cornelissen, R.
    Oulkhouir, Y.
    Greillier, L.
    Kaplan, M. A.
    Talbot, T.
    Monnet, I.
    Hiret, S.
    Baas, P.
    Nowak, A. K.
    Fujimoto, N.
    Tsao, A. S.
    Mansfield, A. S.
    Popat, S.
    Zhang, X.
    Hu, N.
    Balli, D.
    Sanzari, J.
    Zalcman, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1341 - S1342
  • [49] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
    Zalcman, G.
    Oulkhouir, Y.
    Cornelissen, R.
    Greillier, L.
    Cid, J. R. Rodriguez
    Mazieres, J.
    Briggs, P.
    Nowak, A. K.
    Tsao, A.
    Fujimoto, N.
    Peters, S.
    Mansfield, A. S.
    Popat, S.
    Nassar, A.
    Bushong, J.
    Hu, N.
    Spires, T.
    Balli, D.
    Eccles, L.
    Baas, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1438 - S1439
  • [50] A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).
    Long, Georgina V.
    Atkinson, Victoria
    Menzies, Alexander M.
    Guminski, Alexander David
    Sandhu, Shahneen Kaur
    Brown, Michael Paul
    Liaw, Tracy
    Gonzalez, Maria
    Davison, Jill
    Paton, Elizabeth J.
    Scolyer, Richard A.
    Emmett, Louise
    McArthur, Grant A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345